GSK 3996401
Alternative Names: GSK-3996401; GSK-4347859Latest Information Update: 06 Feb 2024
At a glance
- Originator GSK
- Class Anti-inflammatories
- Mechanism of Action Interferon modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Systemic lupus erythematosus
Most Recent Events
- 11 Jan 2024 Phase-I clinical trials in Systemic lupus erythematosus (In volunteers) in United Kingdom (unspecified route) (NCT06188507)
- 09 Jan 2024 Preclinical trials in Systemic lupus erythematosus in United Kingdom (unspecified route) (GlaxoSmithKline pipeline, January 2024)
- 03 Jan 2024 GSK plans a phase I trial for Systemic lupus erythematosus (In volunteers) in United Kingdom in January 2024 (NCT06188507)